Novartis' first-in-class drug Iptacopan to be included in breakthrough therapy
Time of Update: 2022-05-22
On March 14, CDE's official website showed that Novartis' LNP023 capsules are intended to be included in the breakthrough therapy program for C3 glomerulopathy (C3G)
-
-
-
-
-
-
-
-
-
-
-
Potentially best in class!
Time of Update: 2022-05-20
In addition, Ascletis' second 3CLpro drug candidate showed antiviral activity and safety window consistent with ASC11 in Vero E6 cells .
The large variety of anti-gout was "cut in half", and 4 new drugs of class 1 of traditional Chinese medicine were strongly filled
Time of Update: 2022-05-17
Figure 1: Market size of chemical anti-gout preparations in recent years (unit: 100 million yuan) Source: Minet.
In 2022, the "close relatives" of Class 1 innovative drugs will accelerate the launch of the outbreak
Time of Update: 2022-05-17
From the perspective of new improved chemical drugs (excluding new indications) approved from 2020 to the present, there are a total of levoornidazole tablets from Shenghe Pharmaceuticals, olanzapine oral dissolving film from Hansoh, and montelukast from Qilu Pharmaceuticals.
Chia Tai Tianqing's onslaught of innovative drugs This year, 7 class 1 new drugs were approved for clinical use
Time of Update: 2022-05-17
On April 19, CDE's official website showed that Chia Tai Tianqing's Class 1 new drug TQH2722 injection was approved for clinical use and is intended to be used for the treatment of atopic dermatitis .
Hengrui Medicine's Class 1 New Drugs Hit the 30 Billion Antithrombotic Drug Market
Time of Update: 2022-05-15
Market sales of terminal antithrombotic drugs in public medical institutions in China (unit: ten thousand yuan) Source: Minet.
AstraZeneca/Daisankyo ADC therapy plans to be included in the priority review of Class 1 new
Time of Update: 2022-05-12
Breast cancer | AstraZeneca/Daiichi Sankyo ADC therapy proposed for priority review> On April 24, the CDE official
The research and development of class 1 new drugs of traditional Chinese medicine is accelerated!
Time of Update: 2022-05-10
[Pharmaceutical Network Industry News] In recent years, the traditional Chinese medicine industry has been frequently supported by favorable policies, and the research and development of new Chinese medicine class 1
Domestic pharmaceutical companies are attacking class 1 new drugs, and good news in this field continues
Time of Update: 2022-05-02
In recent years, with the continuous improvement of the research and development capabilities of domestic pharmaceutical
Vembrolizumab: A 'first in class' ADC to challenge first-line lymphoma treatment
Time of Update: 2022-05-02
By Arale
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype
In the field of first-in-class, a large number of local pharmaceutical companies are actively deploying
Time of Update: 2022-05-02
In recent years, with the advancement of policies such as the reform of the drug review and approval system and the drug
Arkuda develops potential 'first-in-class' therapy for common Alzheimer's disease
Time of Update: 2022-05-02
Today, Arkuda Therapeutics announced the completion of a $64 million Series B financing BeiGene's 22 Class 1 New Drugs Are Eye-catching, Over 10 New Drugs "Going Overseas to Take the Test" Osaikang has accumulated a lot to release the first class 1 new drug benchmarking 4 billion varieties! Osaikang has accumulated a lot, and the first class 1 new drug is benchmarked against 4 billion varieties! State Food and Drug Administration: Opinions on matters related to the filing of Class I medical devices Qilu's QLS31906 for Class 1 biological drug injection was approved to enter the 100 billion market Tide Pharma's first-class innovative drug for pneumoconiosis was approved for clinical use World-class large petrochemical complex starts construction in Fujian Time of Update: 2022-05-01
million US dollars (about 4 billion yuan) . 22 class 1 new drugs under development are eye-catching, many of which are sprinting for the first domestic BeiGene Some innovative drugs under development
Time of Update: 2022-05-01
with PD-1/L1 antibody showed a significant synergistic anti-tumor effect, and also effectively inhibited the metastasis of cancer cells . In the field of anti-tumor drugs, Osaikang's first class 1
Time of Update: 2022-05-01
with PD-1/L1 antibody showed a significant synergistic anti-tumor effect, and also effectively inhibited the metastasis of cancer cells . In the field of anti-tumor drugs, Osaikang's first class 1
Time of Update: 2022-05-01
On March 2, the General Department of the State Food and Drug Administration issued a public solicitation for comments on the "Announcement on Matters Concerning the Filing of Class I Medical Devices (Draft for Comment)" .
Time of Update: 2022-05-01
On February 18, the CDE official website showed that QLS31906, a class 1 biological drug for injection of Qilu Pharma, has obtained an implied license for clinical trials and is intended
Time of Update: 2022-04-30
Ted Pharmaceuticals revealed that TDI01 has completed Phase I clinical trials in the United States with good safety, and is currently conducting bridging trials in China .
Time of Update: 2022-04-29
The author learned from Gulei Development Zone, Zhangzhou, Fujian Province that the joint venture between the global petrochemical giant Saudi Basic Industries Corporation (SABIC) and Fujian Energy and Chemical Group Fujian Zhongsha Petrochemical Co.
Welcome to ECHEMI